ADCs are a class of biopharmaceuticals that combine monoclonal antibodies with potent cytotoxic agents. This article traces their development through three generations, explores reasons behind successes and failures in clinical trials, and underscores the complexity of selecting suitable targets. By integrating technological advances in AI, single-cell sequencing, and combination therapies, researchers aim to widen ADCs' therapeutic window and application scope.
Key points of the review include:
The development of ADCs represents a critical frontier in targeted cancer therapy, but progress is hindered by biological complexity, off-target effects, and resistance mechanisms. This review emphasizes that precise antigen selection, supported by cutting-edge technologies like single-cell sequencing and artificial intelligence, is essential to minimize toxicity and improve efficacy. Future success hinges on integrating these strategies with innovations in antibody engineering and drug-linker chemistry, as well as leveraging combination therapies. Claudin-18 serves as a potential model for safer targeting, while ongoing work continues to refine and expand the ADC toolkit for broader and more effective cancer applications. The work entitled “ The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts ” was published on Protein & Cell (published on Jan. 15, 2025).
Protein & Cell
Experimental study
Not applicable
The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts
15-Jan-2025